Progress and prospects: hurdles to cardiovascular gene therapy clinical trials
Authors:
- 14 April 2011
- journal article
- review article
- Published by Springer Nature in Gene Therapy
- Vol. 18 (8) , 743-749
Abstract
Several gene therapy approaches have been designed for the treatment of cardiovascular diseases. A positive finding is that the safety of cardiovascular gene therapy has been excellent even in long-term follow-up. However, several hurdles to this field are still present. A major disappointing feature of the trials is that while preclinical and uncontrolled phase-I gene therapy trials have been positive, none of the randomized controlled phase-II/III cardiovascular gene therapy trials have shown clinically relevant positive effects. Low gene transfer efficiency seems to be associated with several trials. A sophisticated efficient delivery method for cardiovascular applications is still lacking and only low concentrations of the gene product are produced in the target tissues. Only a few gene therapy vectors can be produced in large scale. In addition, inflammatory reactions against vectors and inability to regulate gene expression are still present. Furthermore, a strong placebo effect is affecting the results in gene therapy trials, and long-term trials have become more difficult to conduct because of the multiplicity of therapies applied simultaneously on the patients. This review summarizes advances and obstacles of current cardiovascular clinical gene therapy trials.Keywords
This publication has 43 references indexed in Scilit:
- Capsid-Incorporation of Antigens into Adenovirus Capsid Proteins for a Vaccine ApproachMolecular Pharmaceutics, 2010
- VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN TrialMolecular Therapy, 2009
- Hotline sessions presented at the American College of Cardiology Congress 2009Clinical Research in Cardiology, 2009
- VEGF inhibition: insights from preclinical and clinical studiesCell and tissue research, 2008
- Current Status of Cardiovascular Gene TherapyMolecular Therapy, 2007
- AAV Serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effectGene Therapy, 2006
- Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectorisJACC, 2005
- Improved Vascular Gene Transfer With a Helper-Dependent Adenoviral VectorCirculation, 2004
- Vascular endothelial growth factor‐C gene therapy restores lymphatic flow across incision woundsThe FASEB Journal, 2004
- Gene transfer into rabbit arteries with adeno‐associated virus and adenovirus vectorsThe Journal of Gene Medicine, 2004